Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 66Active not recruiting 15Recruiting 10Terminated 7Unknown 4Withdrawn 3Not yet recruiting 1

Sponsor Class

OTHER 18INDUSTRY 7NIH 4OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Specimen Handling 7Magnetic Resonance Spectroscopy 6Radiotherapy 5Biopsy 4Radiation 3Cytarabine 3Cyclophosphamide 3venetoclax 2Vincristine 2Standard of Care 2Spinal Puncture 2Practice Guidelines as Topic 2High-Energy Shock Waves 2Daunorubicin 2Azacitidine 2trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1taxane 1sulforaphane 1sacituzumab govitecan 1revumenib 1prednylidene 1pertuzumab 1pembrolizumab 1pegaspargase 1nelarabine 1merphos 1liposomal doxorubicin 1lenvatinib 1gilteritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × NETWORK × Dexamethasone × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡